Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019
Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.
You may also be interested in...
US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.
Congressional objections to proposal join opposition by patient and physician groups.
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.